Release Date: 22/10/14 15:54 Summary: Annual Report to Shareholders Price Sensitive: No Download Document 1.8MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%